糖尿病专业知识宣贯讲义.ppt

糖尿病专业知识宣贯;Classification of diabetes(ADA-1997);Other specific types;Pathogenesis ;Pathology ;Pathophysiology ; Abnormalities in metabolism ; Insulin secretion curve :normal and diabetics ;Clinical Presentation;Natural history of type 2 DM;Models of the onset of two phrases of type 2 DM ;WHO plasma glucose guideline;Comparison of type 1 and type 2 DM;Chronic complications; Mechanism of complications;Hyperglycemia is the essential reason for diabetic complications ; UKPTS：results;Epidemiology of diabetes Macrovascular disease; Hypertension in DM;Diabetic retinopathy－leading course of new cases of blindness Pathogeny：state of illness 、course of disease、age of onset 5 years ：eyeground disease is not common 10 years ：50％eyeground disease 20 years ：80?90％eyeground disease;Classifications (China);Diabetic nephropathy;Stages of diabetic nephropathy(1);Stages of diabetic nephropathy(2);Classification of diabetes neuropathy （1）;Diabetic sensability multiple neuropathy;;Diabetic autonomic neuropathy ;Glucosuria：associated with renal threshold of sugar (only for clue) Ketonuria Blood sugar：plasma glucose，POD HBA1c：2?3 months blood sugar level Fructosamine：2?3 weeks blood sugar level OGTT：2 hour specimen Insulin and C-peptide release test ;Diagnosis;Criteria for diagnosing diabetes;Characteristics of new diabetic diagnostic criteria ;Practical problems in diagnosis;latent autoimmune diabetes mellitus in adults （LADA）;Management;Goals;Principle of treatment;Goals of control;Control actuality of DM in China;Diabetes Management Plan;Phases therapy of DM;Principles of medical nutrition theraphy;Adult-onset diabetes thermal energy supply per day （therm/kg standard weight ）; Nutrition principles of diabetics ;Calculation ;Exercise therapy;Drug therapy;Sulfonylureas: mode of action; Sulfonylureas （SU）： first choice of non-obesity T2DM ;Therapeutic effects of SU;Indications and contraindications of SU;Side effects of SU;Biguanides ：fir